Loading...
Market
Ohtuvayre receives positive ATS coverage by March 31, 2024?
5
Resolution / Starting Odds
Yes • 50%
No • 50%
American Thoracic Society publications or press releases
Story
Verona Pharma's Ohtuvayre COPD Drug FDA-Approved at $2,950/Month
Jun 27, 2024, 09:27 AM
Verona Pharma, $VRNA, received FDA approval for its COPD drug, Ohtuvayre (ensifentrine), with a wholesale price of $2,950 per month. The drug is seen as a future blockbuster, targeting a significant unmet need in COPD treatment. The company is preparing for market launch with a strong sales and marketing strategy.
View original story
Similar markets
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Less than 25% • 25%
25% - 50% • 25%
51% - 75% • 25%
More than 75% • 25%
Signed into law • 25%
Vetoed by President • 25%
Returned to Congress for amendments • 25%
No action taken by March 31, 2025 • 25%
